Sigilon Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
Sigilon Therapeutics (NASDAQ:SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 8:00 a.m. EDT. The event will be held in a virtual format, and a live webcast will be available on the company's website under 'Events and Presentations.' Sigilon focuses on developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, utilizing non-viral engineered cell-based therapies.
- None.
- None.
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in a fireside chat during the Jefferies Virtual Healthcare Conference. The fireside chat will take place on Thursday, June 3 at 8:00 a.m. EDT, in a virtual format.
A live webcast of the fireside chat will be accessible under “Events and Presentations” in the Investors & Media page of the Company's website at www.sigilon.com. A replay of the fireside chat will be available at the same location following the event.
About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Investor Contacts
Rob Windsor
Sigilon Therapeutics, Head of Investor Relations
robert.windsor@sigilon.com
617-586-3837
Mike Biega
Solebury Trout
mbiega@soleburytrout.com
617-913-8890
Media Contact
Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349
FAQ
What is Sigilon Therapeutics participating in on June 3, 2021?
Who will represent Sigilon Therapeutics at the Jefferies Conference?
Where can I watch the fireside chat of Sigilon Therapeutics?
What is the focus of Sigilon Therapeutics' research?
What type of therapies does Sigilon Therapeutics develop?
